Back to search

Article

Primary CD34 <sup>+</sup> cells of patients with VEXAS syndrome are highly sensitive to targeted treatment with TAK-243 and pevonedistat

2025-05-24

Abstract excerpt

Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome is an autoinflammatory disease characterized by somatically acquired UBA1 mutations in hematopoietic stem cells. VEXAS patients present with significant therapeutic challenges such as severe treatment-resistant inflammation and predisposition to myeloid malignancies. In this study, we evaluated the efficacy of TAK-243, a UBA1 inhibitor, and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
37abce78-0fd6-5774-bbd5-2bac0564a8cb
DOI
10.1101/2025.05.22.653244
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Primary CD34 <sup>+</sup> cells of patients with VEXAS syndrome are highly sensitive to targeted treatment with TAK-243 and pevonedistatDOI 10.1101/2025.05.22.653244
Select a neighboring publication to make it the new centre.